Acerus Pharmaceuticals Stock Fundamentals
| ASPCFDelisted Stock | USD 0.22 0.00 0.00% |
Acerus Pharmaceuticals fundamentals help investors to digest information that contributes to Acerus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acerus OTC Stock. The fundamental analysis module provides a way to measure Acerus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acerus Pharmaceuticals otc stock.
Acerus |
Acerus Pharmaceuticals OTC Stock Shares Outstanding Analysis
Acerus Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Acerus Pharmaceuticals Shares Outstanding | 7.71 M |
Most of Acerus Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acerus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Acerus Pharmaceuticals has 7.71 M of shares currently outstending. This is 95.73% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 98.65% higher than that of the company.
Acerus Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acerus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Acerus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acerus Pharmaceuticals competition to find correlations between indicators driving Acerus Pharmaceuticals's intrinsic value. More Info.Acerus Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Acerus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Acerus Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acerus Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Acerus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acerus Pharmaceuticals by comparing valuation metrics of similar companies.Acerus Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Acerus Fundamentals
| Return On Equity | -22.42 | |||
| Return On Asset | -0.54 | |||
| Operating Margin | (8.41) % | |||
| Current Valuation | 49.66 M | |||
| Shares Outstanding | 7.71 M | |||
| Shares Owned By Insiders | 91.41 % | |||
| Price To Book | 20.08 X | |||
| Price To Sales | 2.16 X | |||
| Revenue | (4.13 M) | |||
| Gross Profit | 1 M | |||
| EBITDA | (31.5 M) | |||
| Net Income | (33.82 M) | |||
| Cash And Equivalents | 1.29 M | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 21.14 M | |||
| Debt To Equity | 2.61 % | |||
| Current Ratio | 0.37 X | |||
| Book Value Per Share | (1.80) X | |||
| Cash Flow From Operations | (23.52 M) | |||
| Earnings Per Share | (3.63) X | |||
| Number Of Employees | 14 | |||
| Beta | 1.35 | |||
| Market Capitalization | 2.09 M | |||
| Total Asset | 9.65 M | |||
| Z Score | -9.9 | |||
| Net Asset | 9.65 M |
About Acerus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acerus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acerus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acerus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for mens and womens health. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada. ACERUS PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 14 people.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Acerus Pharmaceuticals information on this page should be used as a complementary analysis to other Acerus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Acerus OTC Stock
If you are still planning to invest in Acerus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acerus Pharmaceuticals' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world |